-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60

Benzinga·08/11/2026 16:14:54
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $52 to $60.